Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena  

作　　者：Arya Mariam Roy Saby George 

机构地区：[1]Division of Hematology and Oncology,Department of Internal Medicine,Roswell Park Comprehensive Cancer Center,Buffalo,NY 14203,USA

出　　处：《Cancer Drug Resistance》2023年第3期642-655,共14页癌症耐药（英文）

摘　　要：The introduction of immune checkpoint inhibitor (ICI) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and has dramatically improved the outcomes of patients. The use of monotherapy or combinations of ICIs targeting PD-1/PD-L1 and CTLA-4, as well as the addition of ICIs with tyrosine kinase inhibitors, has significantly enhanced the overall survival of mRCC patients. Despite these promising results, there remains a subset of patients who either do not respond to treatment (primary resistance) or develop resistance to therapy over time (acquired resistance). Understanding the mechanisms underlying the development of resistance to ICI treatment is crucial in the management of mRCC, as they can be used to identify new targets for innovative therapeutic strategies. Currently, there is an unmet need to develop new predictive and prognostic biomarkers that can aid in the development of personalized treatment options for mRCC patients. In this review, we summarize several mechanisms of ICI resistance in RCC, including alterations in tumor microenvironment, upregulation of alternative immune checkpoint pathways, and genetic and epigenetic changes. Additionally, we highlight potential strategies that can be used to overcome resistance, such as combination therapy, targeted therapy, and immune modulation.

关 键 词：Renal cell carcinoma immunotherapy immune checkpoint inhibitors primary resistance acquired resistance immune exhaustion markers immunosuppressive tumor microenvironment 

分 类 号：R737.11[医药卫生—肿瘤]